Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain.
chronic pelvic pain
dyspareunia
endometriosis
long term dienogest
quality of life
sexual life
Journal
Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514
Informations de publication
Date de publication:
2019
2019
Historique:
received:
05
03
2019
accepted:
06
06
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
20
9
2019
Statut:
epublish
Résumé
The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months. Fifty-four women constituted the study group and were given DNG 2 mg/daily; 38 women were given non-steroidal anti-inflammatory drugs (NSAIDs) and constituted the control group. To define endometriosis-associated pelvic pain, dysmenorrhea and dyspareunia the Visual Analogic Scale (VAS) was used. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess the QoL, sexual function and the sexual distress, respectively. The study included five follow-ups at 3, 6, 12, 18 and 24 months. Slight improvements in chronic pelvic pain, dysmenorrhea and dyspareunia were observed in the study group at 3 months ( Long-term treatment with DNG 2 mg once-daily in women with endometriosis-associated pelvic pain may have positive effects on the QoL and sexual life, confirming the observations of the previous study on the first 6 months of treatment.
Identifiants
pubmed: 31536046
doi: 10.2147/JPR.S207599
pii: 207599
pmc: PMC6681157
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2371-2378Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Eur J Pharmacol. 1999 Dec 10;386(1):33-40
pubmed: 10611461
Mol Hum Reprod. 2001 Apr;7(4):341-7
pubmed: 11279296
Ann Emerg Med. 2001 Dec;38(6):633-8
pubmed: 11719741
J Sex Marital Ther. 2002 Jul-Sep;28(4):317-30
pubmed: 12082670
Hum Reprod. 2005 Oct;20(10):2698-704
pubmed: 15980014
Steroids. 2008 Feb;73(2):222-31
pubmed: 18061638
Gynecol Endocrinol. 2008 Apr;24(4):214-9
pubmed: 18382908
Contraception. 2009 Jan;79(1):29-34
pubmed: 19041438
Reprod Sci. 2009 Apr;16(4):335-46
pubmed: 19196878
Womens Health (Lond). 2010 Jan;6(1):27-35
pubmed: 20001868
Contraception. 2010 Nov;82(5):410-7
pubmed: 20933114
J Clin Pharmacol. 2012 Nov;52(11):1704-13
pubmed: 22128200
Hum Reprod. 2013 May;28(5):1221-30
pubmed: 23442755
Nat Rev Endocrinol. 2014 May;10(5):261-75
pubmed: 24366116
Hum Reprod. 2014 Mar;29(3):400-12
pubmed: 24435778
Fertil Steril. 2014 Apr;101(4):927-35
pubmed: 24630080
Ann N Y Acad Sci. 2014 May;1317:17-23
pubmed: 24738993
Reprod Sci. 2015 May;22(5):626-32
pubmed: 25394646
Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:188-92
pubmed: 25461377
Cochrane Database Syst Rev. 2015 Jul 30;(7):CD001751
pubmed: 26224322
J Endocrinol Invest. 2015 Nov;38(11):1211-8
pubmed: 26337183
Am J Obstet Gynecol. 2016 Feb;214(2):203-211
pubmed: 26364832
J Endocrinol Invest. 2016 Aug;39(8):923-31
pubmed: 27023105
Fertil Steril. 2017 Mar;107(3):537-548
pubmed: 28139239
Fertil Steril. 2017 Mar;107(3):533-536
pubmed: 28162779
Hum Reprod. 2017 Jul 1;32(7):1432-1438
pubmed: 28482063
Int J Womens Health. 2017 May 16;9:323-330
pubmed: 28553145
Clin Obstet Gynecol. 2017 Sep;60(3):485-496
pubmed: 28590310
Clin Obstet Gynecol. 2017 Sep;60(3):524-530
pubmed: 28742584
Aust N Z J Obstet Gynaecol. 2018 Oct;58(5):560-563
pubmed: 29359457
Eur J Contracept Reprod Health Care. 2018 Feb;23(1):24-31
pubmed: 29436865
Expert Opin Pharmacother. 2018 Jul;19(10):1109-1125
pubmed: 29975553
J Clin Epidemiol. 1998 Nov;51(11):1159-65
pubmed: 9817133
Drugs. 1998 Nov;56(5):825-33; discussion 834-5
pubmed: 9829156